Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry.

Diallo R, Schaefer KL, Bankfalvi A, Decker T, Ruhnke M, Wülfing P, Jackisch C, Luttges J, Sorensen PH, Singh M, Poremba C.

Hum Pathol. 2003 Dec;34(12):1299-305.

PMID:
14691916
2.

Secretory carcinoma of the breast: a genetically defined carcinoma entity.

Diallo R, Tognon C, Knezevich SR, Sorensen P, Poremba C.

Verh Dtsch Ges Pathol. 2003;87:193-203.

PMID:
16888913
3.
4.
5.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
6.

Multicentric mammary carcinoma: evidence of monoclonal proliferation.

Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA.

Cancer. 2002 Apr 1;94(7):1910-6.

7.

Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.

Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.

Oncol Rep. 2008 Mar;19(3):651-6.

PMID:
18288397
8.

Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.

Bhargava R, Naeem R, Marconi S, Luszcz J, Garb J, Gasparini R, Otis CN.

Hum Pathol. 2001 Dec;32(12):1344-50.

PMID:
11774167
9.

Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum.

Laé M, Fréneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A.

Mod Pathol. 2009 Feb;22(2):291-8. doi: 10.1038/modpathol.2008.184. Epub 2008 Nov 14.

10.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
11.

Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.

Cornolti G, Ungari M, Morassi ML, Facchetti F, Rossi E, Lombardi D, Nicolai P.

Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):1031-6.

PMID:
17938328
12.

Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.

Skálová A, Stárek I, Vanecek T, Kucerová V, Plank L, Szépe P, Di Palma S, Leivo I.

Histopathology. 2003 Apr;42(4):348-56.

PMID:
12653946
14.

Alterations in the expression of PDCD4 in ductal carcinoma of the breast.

Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O.

Oncol Rep. 2007 Dec;18(6):1387-93.

PMID:
17982621
17.

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.

Prati R, Apple SK, He J, Gornbein JA, Chang HR.

Breast J. 2005 Nov-Dec;11(6):433-9.

PMID:
16297088
18.

The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.

Tong LC, Nelson N, Tsourigiannis J, Mulligan AM.

Am J Surg Pathol. 2011 Apr;35(4):545-52. doi: 10.1097/PAS.0b013e31820e6237.

PMID:
21358301
19.

Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.

Sharif MA, Mamoon N, Mushtaq S, Khadim MT.

J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103. doi: 02.2009/JCPSP.99103.

PMID:
19208313

Supplemental Content

Support Center